Loading clinical trials...
Loading clinical trials...
Phase 3b, Multicenter, Open-label, Single-Arm Expanded Access Protocol of TEPROTUMUMAB (HZN-001)
Conditions
Interventions
Teprotumumab
Locations
8
United States
MACRO Trials
Beverly Hills, California, United States
Bascom Palmer Eye Institute
Miami, Florida, United States
NorthShore University HealthSystem
Skokie, Illinois, United States
Institute of Ophthalmology and Visual Science, Rutgers University New Jersey Medical School
Newark, New Jersey, United States
Eye and Facial Plastic Surgery Consultants
Plymouth Meeting, Pennsylvania, United States
Prisma Health Upstate/Endocrinology Specialists and Thyroid Center
Greenville, South Carolina, United States
Last Updated
June 20, 2024
NCT07423013
NCT06112340
NCT06359795
NCT05012033
NCT06557850
NCT07155668
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions